Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Oncotarget’s Top 10 Papers in 2022 (Crossref Data)

Oncotarget

February 21, 2023
Read Crossref’s Top 10 Oncotarget DOIs in 2022. continue reading »

Oncotarget | Extreme Phenotype Approach Identifies Rare ATR Variants as Potential Male Breast Cancer Susceptibility Alleles

News

February 21, 2023
PRESS RELEASE: On February 7, 2023, a new research paper was published in Oncotarget, entitled, “The ‘extreme phenotype approach’ applied to male breast cancer allows the identification of rare variants of ATR as potential breast cancer susceptibility alleles.” continue reading »

Controlling Glycolytic Flux: Therapy Challenges and Solutions

Trending

February 16, 2023
In a new editorial paper, researchers from the University of Oxford explore challenges and potential solutions for controlling glycolytic flux by blocking lactate transporters in disease therapies. continue reading »

Oncotarget | Novel Prognostic Index to Predict Survival Outcomes in Gastric Cancer Patients

News

February 14, 2023
PRESS RELEASE: On January 31, 2023, researchers from Shimane University and Matsue Red Cross Hospital published a new research paper in Oncotarget, entitled, “Novel inflammation-combined prognostic index to predict survival outcomes in patients with gastric cancer.” continue reading »

Oncotarget | Everolimus Inhibits Angiogenesis and Lymphangiogenesis in TP53 Mutant HNSCC by Downregulating STAT3/HIF-1α/VEGF Pathway

News

February 9, 2023
PRESS RELEASE: On February 2, 2023, a new research paper was published in Oncotarget, entitled, “Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC).” continue reading »